Surgeon-scientists analyze the case of Lawrence Faucette, the second recipient of a genetically modified pig heart, to identify challenges to avoid rejection in future xenotransplants.
Designed for the treatment of pulmonary artery stenosis and aortic coarctation in neonates, infants, and children, the stent can be periodically expanded over time to keep up with vessel growth.
The surgery was associated with a 42% reduction in the risk of heart complications and a 37% reduction in the risk of death in patients with obstructive sleep apnea.
Read More
Stopping aspirin and using ticagrelor alone significantly reduced bleeding risks in high-risk heart patients following heart stent placement.
Read More
The clearance broadens the applicability of the AlphaVac F1885 System in the non-surgical removal of thrombi or emboli from the venous vasculature.
Read More
The FDA approves Boston Scientific Corporation’s AGENT Drug-Coated Balloon for treating coronary in-stent restenosis, marking the first drug-coated coronary balloon approval in the United States.
Read More
The approval marks the first transcatheter replacement device indicated for use in the tricuspid position.
Read More
The 225-cm catheter length expands access points in atherectomy procedures to help reduce access site complications and accelerate patient recovery.
Read More
ShortCut is the first dedicated leaflet modification device to enable TAVR in patients at risk of coronary obstruction, according to Pi-Cardia.
Read More
The device, designed by a team of physicians and engineers at Boston University, possesses shape-shifting capabilities that allow it to be maneuvered through complex anatomy while maintaining enough stability to accomplish surgical objectives within the heart.
Read More
Women with atrial fibrillation undergoing a procedure called pulsed field ablation have just as good outcomes as men, a new study finds.
Read More